Antithrombotics and diabetes treatments responsible for most emergency adverse drug events: NEJM

In an article published in the New England Journal of Medicine (NEJM) on 24 November 2011, the authors report that in older Americans, warfarin is the drug that is most commonly responsible for emergency hospital admissions related to drug side effects.  … Continue reading

Albiglutide doesn’t match Victoza in phase 3 diabetes trial

GlaxoSmithKline (GSK) announced on 16 November 2011, that albiglutide did not meet its primary endpoint of non-inferiority compared with liraglutide (Victoza, Novo Nordisk) in the HARMONY 7 trial – a head-to-head comparison of the 2 GLP-1 agonists, and the first of 8 phase … Continue reading

Promising data on Lilly’s CETP inhibitor, evacetrapib — JAMA

Phase 2 data from a trial comparing evacetrapib, a new cholesteryl ester transfer protein inhibitor (CETPi), to placebo (in addition to statin therapy in most patients) was presented at the AHA congress and published in the Journal of the American Medical Association … Continue reading